- Home
- TROO vs AVIR Comparison
TROO vs AVIR Comparison
Compare TROO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- AVIR
- Stock Information
- Founded
- TROO 2005
- AVIR 2012
- Country
- TROO Hong Kong
- AVIR United States
- Employees
- TROO N/A
- AVIR N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TROO Technology
- AVIR Health Care
- Exchange
- TROO Nasdaq
- AVIR Nasdaq
- Market Cap
- TROO N/A
- AVIR 273.0M
- IPO Year
- TROO N/A
- AVIR 2020
- Fundamental
- Price
- TROO $0.66
- AVIR $3.74
- Analyst Decision
- TROO
- AVIR Hold
- Analyst Count
- TROO 0
- AVIR 1
- Target Price
- TROO N/A
- AVIR $6.00
- AVG Volume (30 Days)
- TROO 47.0K
- AVIR 413.9K
- Earning Date
- TROO 07-15-2025
- AVIR 08-06-2025
- Dividend Yield
- TROO N/A
- AVIR N/A
- EPS Growth
- TROO N/A
- AVIR N/A
- EPS
- TROO N/A
- AVIR N/A
- Revenue
- TROO $10,073,000.00
- AVIR N/A
- Revenue This Year
- TROO N/A
- AVIR N/A
- Revenue Next Year
- TROO N/A
- AVIR N/A
- P/E Ratio
- TROO N/A
- AVIR N/A
- Revenue Growth
- TROO 182.24
- AVIR N/A
- 52 Week Low
- TROO $0.49
- AVIR $2.46
- 52 Week High
- TROO $4.89
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- TROO 42.17
- AVIR 75.75
- Support Level
- TROO $0.65
- AVIR $3.43
- Resistance Level
- TROO $1.00
- AVIR $3.80
- Average True Range (ATR)
- TROO 0.06
- AVIR 0.14
- MACD
- TROO -0.02
- AVIR 0.03
- Stochastic Oscillator
- TROO 3.57
- AVIR 78.46
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).